Myriad Expands its Companion Diagnostic Collaboration with AstraZeneca and Merck
Shots:
- AstraZeneca & Merck will utilize Myriads’ BRAC Analysis CDx to identify germline BRCA mutations in men who have mCRPC cancer- enrolled in Phase III PROfound (NCT02987543) study
- In 2007- Myriad collaborates with AZ for BRAC Analysis CDx to be used as a companion diagnostic to Lynparza (olaparib) and the combination has received approval from MHLW & FDA for different indications in oncology
- Myriad’s BRACAnalysis CDx is an in vitro diagnostic used for detection of germline BRCA1 and BRCA2 variant and provide a clinical interpretation of the identified variants. Myriad plans to file sPMA to FDA for BRACAnalysis CDx used as a companion diagnostic to Lynparza (olaparib) in mCRPC patients
Ref: Myriad | Image: AstraZeneca
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com